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Abstract 
Autosomal dominantly inherited exonic mutations in the amyloid precursor protein (APP) 
gene may provide a relatively homogeneous patient pool for future therapeutic studies. 
Accordingly, the report of newly diagnosed families with APP gene mutations may have a 
special relevance. This case study aims at the first detailed phenotypic description of the 
Val717Phe mutation in the APP gene apropos of the first detected Hungarian family with this 
mutation. The symptoms of the proband consisted of memory impairment, disorientation, 
reduced attention, language impairment, apraxia, seizure, myoclonus, tongue protrusion and 
Parkinsonism starting to develop at the beginning of her 40s. The other affected members of 
the family presented similar alterations. These clinical characteristics, i.e., amnestic 
Alzheimer’s disease phenotype with seizures, myoclonus and Parkinsonism, mostly 
resemble that of caused by Thr714Ile and Ile716Phe mutations with an early onset and severe 
symptoms and signs. In addition to prognostic and future therapeutic aspects, the 
identification of these conditions may have a special importance with regard to 
presymptomatic genetic counselling as well. 
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1. Introduction 
Autosomal dominantly inherited Alzheimer’s disease (AD) is characterized by early onset 
(under the age of 65 years) and accounts for approximately 0.5% of all AD cases1. The 
underlying genetic alterations include mutations in the presenilin-1 (PSEN-1), PSEN-2 and 
amyloid precursor protein (APP) genes and duplication in the APP gene, out of which APP 
gene mutations are responsible for 18% of these genetic cases  with a wide geographical 
distribution2 (http://www.molgen.vib-ua.be/ADMutations; 
http://www.alzforum.org/mutations). Although the clinical features of APP gene mutations 
may be heterogeneous (Suppl. Table 1), the most prevalent symptoms are memory 
impairment, disorientation, language disturbances, apraxia, myoclonus, seizures, dyscalculia, 
Parkinsonism, apathy, depressive mood and aggressive behavior1 (Suppl. Table 1). The age of 
onset and disease duration are variable as well, with a typical onset in their 40s and 50s 
(range: 30-82 years of age) and 10 years of duration (range: 2-18 years), respectively (Suppl. 
Table 1). Although the site of the mutation and the type of amino acid change clearly seems to 
affect the clinical characteristics (Suppl. Table 1), there may be several other influencing 
factors as well. The report of new families is clearly relevant in terms of better understanding 
of disease characteristics. Accordingly, the aim of the current study is to provide a detailed 
phenotypic description of the first Hungarian patient diagnosed with familial AD caused by 
the Val717Phe mutation in the APP gene. 
 
2. Clinical details 
The 48-year-old female patient (the proband, III-2 in Fig. 1) was first admitted to our clinic 
with the aim of the diagnostic work-up of her unknown cognitive disorder in 2015. Her 
symptoms started to develop at the beginning of her 40s. Besides the progressive deterioration 
of her memory functions, serious language impairment, sparing the sensorial part in some 
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extent evolved as well. Two years back her speech was almost incomprehensible. An epileptic 
seizure was reported one month prior to her admission and her relatives also regularly 
recognized myoclonus-like jerks. There is not any other relevant condition in her case history. 
With regard to her family history, the presence of an autosomal dominantly inherited 
neurocognitive disorder can be identified (Fig. 1). Her elder sister (III-1), her mother (II-1), 
her aunt (II-2) and one of her uncles (II-3) died at the age of 48, 61, 61 and 65 years of their 
age, respectively. The symptoms of patient III-1 started to develop at the beginning of her 40s 
as well. Initially she presented memory problems during household activities. Later, serious 
progressive language impairment with considerably reduced communication abilities, 
unspecified movement disorder, myoclonus-like jerks, epileptic seizures and agitation with 
aggressive behavior also developed. The symptoms of patients II-1, II-2 and II-3 were very 
similar to that of patients III-1 and III-2, but the symptoms started to develop later, at the 
beginning of their 50s. Patient II-1 was bedridden following femoral bone fracture in her last 
4 years. Patient II-3 presented only memory impairment and disturbance of consciousness for 
several years following the onset of these symptoms. 
On examination, our female patient presented severe impairment of short-term memory, 
disorientation, reduced attention, severe motor dysphasia or apraxia of speech (cannot be 
differentiated), apraxia affecting several modalities (ideational, ideomotor, dressing, 
constructional and limb kinetic), symmetric severe hypo- and bradykinesis, rigidity 
(Parkinsonism), hypomimia and occasional tongue protrusion. The clinical phenomena were 
consistent with Alzheimer’s disease. 
On the current admission, detailed neuropsychological assessment could not be implemented 
due to the severity of cognitive impairment. However, Mini-Mental State Examination, 
Addenbrooke’s Cognitive Examination and Clock-Drawing Test were performed 2 years 
before with 9/30 points, 28/100 points (orientation: 4/10 points, attention/concentration: 1/8 
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points, memory 1/35 points, verbal fluency: 2/14 points, language: 20/28 points, 
visuoconstructional abilities: 0/5 points) and 0/10 points, respectively. The skull MRI 
revealed generalized atrophy (Fig. 2). The EEG demonstrated temporo-parieto-occipital 
triphasic and delta waves and occasional left temporo-parieto-occipital sharp waves. The 
specific CSF diagnostics yielded normal hTAU (366 pg/ml), normal pTAU (50 pg/ml) and 
decreased β-amyloid(1-42) (443 pg/ml) levels. The genetic testing revealed a known pathogenic 
missense mutation in the APP gene in exon 17 (c.2149 G>T, p.Val717Phe). 
 
3. Discussion 
AD is a currently incurable condition with a relatively heterogeneous clinical phenotype. It 
affects a significant portion of mainly the elderly population resulting in high socioeconomic 
burden. Only symptomatic therapy is available and there is a great scientific effort to develop 
causative therapies. Although the autosomal dominantly inherited exonic mutations in the 
APP gene are responsible for only a very small percentage of Alzheimer’s disease, but the 
pathogenic basis of disease development, i.e., alterations in APP processing, β-amyloid 
production (Aβ) and/or change in the ratio between Aβ1-42/Aβ1-40 are well-established in these 
cases3. Accordingly, the identification of these patients may yield a relatively homogeneous 
patient pool for future pharmaceutical studies4. Furthermore, the detailed clinical description 
of each mutation (Suppl. Table 1) may have an important prognostic value as well. 
With regards to the Val717Phe mutation of the APP gene, only limited clinical data are 
available from previous reports5,6: almost exclusively, memory impairment was described 
with an approximate symptom onset at the beginning of their forties. In addition to this 
seemingly essential alteration in AD, patients in the currently presented family were 
demonstrated to have symptoms related to the impairment of other three cognitive domains as 
well (reduced attention, language impairment, apraxia). Perception and social interactions 
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were not affected at all. Furthermore, other prominent psychiatric and neurological 
alterations, such as disturbance of consciousness, agitation with aggressive behavior, seizure, 
myoclonus, Parkinsonism and occasional tongue protrusion were present as well. Seizure and 
myoclonus are well delineated phenomena in AD including the familial forms7. A 
prospective study demonstrated that early onset familial AD patients had an 87-fold 
increase in seizures compared to the general population8. The altered processing of APP 
may be the mechanistic link between the development of cognitive dysfunction and 
seizures7. The development of Parkinsonism in patients with certain mutations in the 
APP gene is a well-known phenomenon as well and may be the consequence of Lewy 
body formation in addition to AD pathology9. Unfortunately, post mortem specimens 
are not available for neuropathological assessment in the presented pedigree, so this 
hypothesis, i.e. the presence of Lewy body formation in the background of Parkinsonian 
symptoms in this family cannot be verified. There are three mutations (Thr714Ile, 
Val715Met, Ile716Phe), where the clinical phenotype is quite similar to that of in case of 
Val717Phe mutation, and diverse alterations in case of Val717Ile mutation show a 
considerable overlap as well (Suppl. Table 1). The Thr714Ile, Ile716Phe and Val717Phe 
mutations can be characterized by the lowest age of onset out of the mutations where at least 2 
independent affected families are presented. Accordingly, excluding those autosomal 
dominant exonic mutations in the APP gene preferentially causing intracerebral hemorrhage 
due to cerebral amyloid angiopathy at young age, Ile716Phe, Val717Phe and especially 
Thr714Ile mutations seems to have the worst prognosis. The latter one is characterized by the 
highest increase in CSF Aβ1-42/Aβ1-40 ratio3. With regard to biomarkers in the present 
study, the CSF Aβ(1-42) content of the proband decreased characteristically, but not as 
much as it may be expected in light of the severe clinical phenotype. However, it has 
been previously demonstrated that CSF β-amyloid(1-42) level did not correlate either with 
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severity or rate of progression of dementia10. 
The identification of causative mutations in the background of clinical phenomena may 
provide a possibility for presymptomatic genetic counselling as well, involving clearly early 
onset cases of AD11. However, this option may have both advances and dilemmas4,12. The 
current guidelines mostly promote strictly regulated presymptomatic genetic testing in early 
onset autosomal dominantly inherited AD13, which is always suggested to be carried out on 
individual basis following a detailed counselling and the acquisition of written informed 
consent. Accordingly, presymptomatic genetic counselling and testing was carried out in 
possible carriers (IV-2, IV-3), and proved the lack of pathogenic mutation in the APP gene. 
Although in light of the age and mental and cognitive status of the family members III-4 and 
III-5, the presence of pathogenic Val717Phe is improbable, the daughter (IV-4) and son (IV-
5) of the family member III-4 even want to certainly exclude the possibility of carrying that 
mutation. However, one potential mutation carrier (V-1) rejected genetic counselling and 
testing. 
In conclusion, this case study reports the first detailed clinical description of Val717Phe 
mutation, demonstrating amnestic AD phenotype with seizures, myoclonus and 
Parkinsonism, and yields an overview of related autosomal dominantly inherited exonic 
mutations in the APP gene. 
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7. Figure legend 
Fig. 1. Pedigree of the assessed family. The generations are indicated with Roman numbers 
while individuals in each generation with Arabic numbers. The deceased members are 
crossed. The patients demonstrating symptoms are in black. The age at death (d.) and the 
current age of patients in years (y) are indicated where available. The proband is indicated 
with p, whereas the individuals seeking genetic testing with arrows. The results (positive (+) 
or negative (-)) of genetic examination (E) for the p.V717F mutation is also demonstrated. 
Family members, where the presence of pathogenic mutation cannot be certainly excluded 
and genetic testing was not performed, are indicated with question mark. 
 
Fig. 2. T2-weighted skull magnetic resonance imaging (1.5 Tesla) of the proband with 
Val717Phe mutation in the amyloid precursor protein gene. The main characteristic 
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feature is generalized brain atrophy. 
